electroCore, Inc. (ECOR) Stock AnalysisECORStock AnalysiselectroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

electroCore, Inc. is currently not a strong buy due to mixed signals. The current price is $9.62, with a recent 5-day change of -8.51%, indicating short-term weakness. However, the stock has shown a year-to-date increase of 111.54%, suggesting strong long-term potential. The RSI is at 48.23, indicating a neutral position, and the forward P/E ratio is extremely high at 384.62, which raises concerns about valuation. The main risk is the significant insider selling, which has increased by 666.36% over the last month, indicating potential lack of confidence from insiders.

2 analysts cover ECOR: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 15.00.